Evidence map›Paper›PMID 32983964›Full record

ArticleFrontiers in oncology2020

Allelic Imbalance Analysis in Liquid Biopsy to Monitor Locally Advanced Esophageal Cancer Patients During Treatment.

Elisa Boldrin, Matteo Curtarello, Matteo Fassan, Massimo Rugge, Stefano Realdon, Rita Alfieri, Alberto Amadori, Daniela Saggioro

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Elisa BoldrinImmunology and Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Matteo CurtarelloImmunology and Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Matteo FassanDepartment of Medicine (DIMED), Surgical Pathology and Cytopathology, University of Padova, Padova, Italy.
Massimo RuggeDepartment of Medicine (DIMED), Surgical Pathology and Cytopathology, University of Padova, Padova, Italy.
Stefano RealdonEndoscopy Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Rita AlfieriOncological Surgery, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Alberto AmadoriImmunology and Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Daniela SaggioroImmunology and Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Oncologico Veneto · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophageal cancer (EC) is a highly aggressive tumor, and the current monitoring procedures are partially inadequate to evaluate treatment efficacy. The aim of this study was to investigate whether allelic imbalance analysis in liquid biopsy could be used as an additional tool to monitor tumor burden in EC patients. For this purpose, circulating cell-free DNA (cfDNA) from 52 patients with a locally advanced EC, which underwent neoadjuvant treatment and resection, was analyzed. Data from four representative longitudinally followed patients are also reported. Furthermore, 17 DNAs from formalin-fixed paraffin-embedded (FFPE) tumor samples were analyzed and compared to time-matched cfDNAs. To look for allelic imbalance, which is the main genetic alteration in both EC histotypes, we used a panel of five microsatellites (MSs) and three single-nucleotide polymorphisms (SNPs) near genes described as frequently altered. The Fisher exact and Mann-Whitney

Indexed as

allelic imbalancecirculating cell free DNA (cfDNA)esophageal adenocarcinoma (EADC)esophageal canceresophageal squamous cell carcinoma (ESCC)liquid biopsylongitudinal studiesloss of heterozygosis (LOH)

Identifiers

PMID32983964
PMCPMC7484474
OpenAlexW3080545587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.